Bayer is in a race in the Factor XI inhibitor category with other developers, including Bristol-Myers Squibb and Johnson & Johnson with milvexian – also in a phase 3 programme called LIBREXIA ...

New anti-factor XI anticoagulants are currently in development and show promise for preventing ischemic risk. However, will they become widely used, or remain limited to niche treatments?

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The anticoagulant – codenamed MK-2060 – is a monoclonal antibody designed to inhibit Factor XI and is currently in a phase 2b trial in ESRD patients on dialysis, who often need to be treated ...